Medicines NZ Welcomes Fourth TPP Negotiation Round

Published: Mon 6 Dec 2010 03:19 PM
Medicines New Zealand Welcomes Fourth TPP Negotiation Round
Medicines New Zealand is closely following the fourth round of negotiations for the Trans Pacific Partnership (TPP) being held in Auckland this week.
“As the organisation representing innovative pharmaceutical companies in New Zealand we hope that the negotiations will lead to a high quality, comprehensive agreement that scores wins for all the parties” Medicines New Zealand Chief Executive Denise Wood says. “Free trade leads to better global cooperation, competition and economic growth.”
Addressing media interest in the question of PHARMAC reform in the context of the TPP negotiations, Mrs Wood noted that it is absolutely not the case that the industry wants to see PHARMAC dismantled. “The pharmaceutical industry works constructively with bulk purchasing agencies in many markets around the world and such models are common place. That said, the pharmaceutical industry believes if there was greater prioritisation of health outcomes in New Zealand – prevention, treatment and early intervention – through better access to innovative medicines, there would be savings across the health sector and all the other benefits of keeping people healthy, productive and able to enjoy a good quality life.
MedicinesNZ has noted in the past that on average, OECD countries spend 18% of their health budgets on pharmaceuticals. New Zealand’s expenditure on pharmaceuticals as a percentage of the total health budget – around 6% - places it almost at the bottom of the OECD. The result of this is that, in some instances, New Zealand patients do not have access to the most appropriate medicine to treat their condition or miss out on treatments altogether. Unless they do the research themselves, it may be difficult for the average Kiwi to even be aware that there is a drug to treat a problem
Mrs Wood commented that “New Zealand needs to formally acknowledge the role of pharmaceuticals in reducing other costs in the healthcare system and the role of innovative medicines in delivering the best possible health outcomes. We would like to see procurement and pricing policies examined in that context.”
Speaking about what the pharmaceutical industry would like to see, Ms Wood said “the industry seeks an environment where New Zealand’s pharmaceutical management agency is more accountable, transparent and more open to innovative medicines.” She stressed that small changes to the PHARMAC model, along the lines of those negotiated in other trade agreements would improve the situation.

Next in New Zealand politics

Govt Moves On Drug Checking To Keep Young New Zealanders Safer This Summer
By: New Zealand Government
13 Parties Charged By WorkSafe New Zealand Over Whakaari/White Island Tragedy
By: WorkSafe NZ
Progress On Pay Equity For DHB Staff
By: New Zealand Government
Stuff Holds Itself Accountable For Wrongs To Māori
By: Stuff
New Zealand Government To Declare A Climate Emergency
By: New Zealand Government
Crown Accounts Reflect Govt’s Careful Economic Management
By: New Zealand Government
ACT Supports Pill Testing Bill
By: ACT New Zealand
Legal Drug Checking This Festival Season Will Help Protect Our Young People: Green Party
By: Green Party
Timely Decision On Festival Drug Checking Will Save Lives
By: NZ Drug Foundation
Whakaari / White Island Eruption 22nd Death
By: New Zealand Police
Health Minister Priorities Welcomed
By: Association of Salaried Medical Specialists
More Accessible Pay Equity Measures Come Into Force
By: New Zealand Government
Māori Language Commission Welcomes Stuff Announcement
By: Te Taura Whiri i te Reo Maori
Climate Change An Economic Issue; Critical For The Planet’s Future
By: Make Lemonade
Climate Emergency Declaration A Win But Needs Action
By: Greenpeace New Zealand
View as: DESKTOP | MOBILE © Scoop Media